• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
CONCLUSIONS: Globally, Lp(a) is measured in a small minority of patients with ASCVD and is highest in black, younger and female patients. More than 25% of patients had levels exceeding the established threshold for increased cardiovascular risk, approximately 50 mg/dL or 125 nmol/L.PMID:36252994 | DOI:10.1136/openhrt-2022-002060
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Steven E Nissen Kathy Wolski Leslie Cho Stephen J Nicholls John Kastelein Eran Leitersdorf Ulf Landmesser Michael Blaha A Michael Lincoff Ryuichi Morishita Sotirios Tsimikas Junhao Liu Brian Manning Plamen Kozlovski Anastasia Lesogor Tom Thuren Taro Shiba Source Type: research

Real-world, feasibility study to investigate the use of a multidisciplinary app (Pulsara) to improve prehospital communication and timelines for acute stroke/STEMI care
Conclusions In this Australian-first study, uptake of the digital communication app was strong, patient-centred care timelines improved, although door-to-treatment times remained similar.
Source: BMJ Open - July 18, 2022 Category: General Medicine Authors: Bladin, C. F., Bagot, K. L., Vu, M., Kim, J., Bernard, S., Smith, K., Hocking, G., Coupland, T., Pearce, D., Badcock, D., Budge, M., Nadurata, V., Pearce, W., Hall, H., Kelly, B., Spencer, A., Chapman, P., Oqueli, E., Sahathevan, R., Kraemer, T., Hair, C. Tags: Open access, Communication Source Type: research

EE352 Projecting the Incidence and Costs of Major Cardiorenal Complications of Type 2 Diabetes with Widespread GLP-1 RA and SGLT2I Use
Whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose co-transporter 2 inhibitors (SGLT2is) are cost-effective when considering solely their cardiorenal benefits is unknown. We projected the incidence and costs of hospitalisation for myocardial infarction (MI), stroke, and heart failure (HF), and end-stage kidney disease (ESKD) among people with type 2 diabetes under scenarios of widespread use of these drugs, from an Australian healthcare perspective.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: J Morton, C Marquina, JE Shaw, D Liew, Z Ademi, D Magliano Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
CONCLUSIONS: PPV engenders a long-lasting increase in anti-pneumococcal IgG, and to a lesser extent, IgM titres, as well as a transient increase in anti-OxLDL IgM antibodies. However, there were no detectable changes in surrogate markers of atherosclerosis at the 2-year follow-up. Long-term, prospective follow-up of clinical outcomes is continuing to assess if PPV reduces CVD events.PMID:35290813 | DOI:10.1016/j.atherosclerosis.2022.02.011
Source: Atherosclerosis - March 15, 2022 Category: Cardiology Authors: Shu Ren Philip M Hansbro Wichat Srikusalanukul Jay C Horvat Tegan Hunter Alexandra C Brown Roseanne Peel Jack Faulkner Tiffany-Jane Evans Shu Chuen Li David Newby Alexis Hure Walter P Abhayaratna Sotirios Tsimikas Ayelet Gonen Joseph L Witztum John Attia Source Type: research

Impact of COVID-19 lockdowns on hospital presentations and admissions in the context of low community transmission: evidence from time series analysis in Melbourne, Australia
Conclusions Our analyses suggest citizens were willing and able to present with life-threatening conditions during Melbourne’s lockdowns, and that switching to telemedicine did not cause widespread spill-over from primary care into ED. During a pandemic, lockdowns may not inhibit appropriate hospital attendance where rates of infectious disease are low.
Source: Journal of Epidemiology and Community Health - March 10, 2022 Category: Epidemiology Authors: Collyer, T. A., Athanasopoulos, G., Srikanth, V., Tiruvoipati, R., Matthews, C., Mcinnes, N., Menon, S., Dowling, J., Braun, G., Krivitsky, T. A., Cooper, H., Andrew, N. E. Tags: COVID-19 Original research Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE) is a double-blind, randomised controlled trial (RCT) of PPV in preventing ischaemic events. Participants received PPV or placebo once at baseline and are being followed-up for incident fatal and non-fatal myocardial infarction or stroke over 6 years.
Source: Atherosclerosis - March 5, 2022 Category: Cardiology Authors: Shu Ren, Philip M. Hansbro, Wichat Srikusalanukul, Jay C. Horvat, Tegan Hunter, Alexandra C. Brown, Roseanne Peel, Jack Faulkner, Tiffany-Jane Evans, Shu Chuen Li, David Newby, Alexis Hure, Walter P. Abhayaratna, Sotirios Tsimikas, Ayelet Gonen, Joseph L. Source Type: research

How Virtual Reality Is Expanding Health Care
Clinicians can help patients recover from strokes while they’re anywhere in the world—even states or countries far away from each other—by using a combination of robotics and virtual-reality devices. It’s happening at Georgia Institute of Technology, where Nick Housley runs the Sensorimotor Integration Lab. There, patients undergoing neurorehabilitation, including those recovering from a stroke, are outfitted with robotic devices called Motus, which are strapped to their arms and legs. The goal: to speed up recovery and assist with rehabilitation exercises. Patients and practitioners using the syste...
Source: TIME: Health - March 4, 2022 Category: Consumer Health News Authors: Sascha Brodsky Tags: Uncategorized healthscienceclimate Source Type: news

Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.PMID:35020806 | DOI:10.1093/ajhp/zxac010
Source: American Journal of Health-System Pharmacy : AJHP - January 12, 2022 Category: Drugs & Pharmacology Authors: Kirubel Hailu Chad Cannon Sarah Hayes Source Type: research

Associations of Serum Testosterone and Sex Hormone-Binding Globulin With Incident Cardiovascular Events in Middle-Aged to Older Men
CONCLUSION: Men with lower total testosterone concentrations were not at increased risk for MI, stroke, HF, or MACE. Calculated free testosterone may be associated with risk for MACE. Men with lower SHBG concentrations have higher risk for MI but lower risk for IS and HF, with causality to be determined.PRIMARY FUNDING SOURCE: Western Australian Health Translation Network, Medical Research Future Fund, and Lawley Pharmaceuticals.PMID:34958606 | DOI:10.7326/M21-0551
Source: Annals of Internal Medicine - December 27, 2021 Category: Internal Medicine Authors: Bu B Yeap Ross J Marriott Leen Antonio Suchitra Raj Girish Dwivedi Christopher M Reid Bradley D Anawalt Shalender Bhasin Adrian S Dobs David J Handelsman Graeme J Hankey Robin Haring Alvin M Matsumoto Paul E Norman Terence W O'Neill Claes Ohlsson Eric S O Source Type: research

Pages: 1  2  3  4  5  6  7